A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

Covalent BTK inhibitors and Bcl-2 inhibitors are primary treatments for CLL, but alternatives are needed for relapsed or refractory cases. Treatment sequencing is vital, with potential switches ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.Acalabrutinib (Calquence, AstraZeneca) tablets ...

Imbruvica is a prescription drug used in adults with chronic lymphocytic leukemia (CLL), a type of cancer that starts in the bone marrow. The drug is available in three oral forms: a capsule, tablet, ...

A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective. Using a genetic assay for risk ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...